ERCC1Excision Repair Cross-Complementation Group 1
ERCC1Excision-Repair, Complementing Defective, in Chinese Hamster, 1
References in periodicals archive ?
The ERCC1 and RRM1 concentrations in each case were estimated by a semi-quantitative H-score according to the intensity of staining.
6,7,16) The 8F1 antibody not only recognizes ERCC1 but also recognizes a nuclear membrane protein PCYT1A.
RT PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Results: Our meta-analysis found that ERCC1 rs3212986 AA genotype was significantly associated with increased risk of glioma compared with CC genotype and the pooled OR (95%CI) was 1.
2] Nonstandard abbreviations: CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; CK, cytokeratins; DAPI, 4',6-diamidino-2-phenylindole; HER2, human epidermal growth factor receptor 2; FACS, fluorescence-activated cell sorting; ERCC1, excision repair cross-complementation group 1; MUC1, mucin 1, cell surface associated; CA, cancer antigen.
The genes evaluated for both extracts included BCL-2, p53, PDGF, ICAM-1, ERCC1, TNF[alpha], and VEGF.
Ambas fracciones son codificadas por genes localizados en cromosomas diferentes y que se expresan en momentos opuestos del ciclo celular, relacionandose en forma intima con la expresion del mARN del ERCC1 (195,196).
Los genes ERCC1 (Excision Repair Cross-Complementing 1), RR (Ribonucleotide Reductase y su subunidad RRM1) y BRCA1 (Breast Cancer 1) intervienen de forma crucial en las vias de reparacion del ADN.
The PRECIS profiles include clinically relevant tumor biomarkers EGFR, ALK rearrangement, ALK-mutation for resistance, KRAS, BRAF, NRAS, PIK3CA, 10q23 deletion, c-MET, DDR2, and chemo response biomarkers ERCC1 and RRM1 that aid in characterizing disease pathways and proper molecular targeted therapies.
Thus, we searched the available articles and performed the meta-analysis to elucidate the prognostic role of ERCC1 expression in patients with CRC.
Objective: We aimed to analyze the expression of ERCC1 RRM1 and TUBB3 in 305 patients with advanced non-small cell lung cancer (NSCLC) and investigate whether these genes can be used as biomarkers for predicting tumor response and clinical outcome.
Expression of both the ERCC1 protein or the ERCC1 transcript has been extensively studied in primary tumor tissue of several cancer entities and has been proposed as a potential predictor for response to platinum-based chemotherapy.